Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152)
Implementation of the American Taxpayer Relief Act of 2012 (Pub. L. 112-240, H. R. 8)
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. 112-144)
S. 957, Drug Supply Chain Security Act; H. R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013
S. 959, Pharmaceutical Compounding Quality and Accountability Act and as they relate to the tracking and tracing of pharmaceutical drugs.
Ongoing discussions surrounding next steps for protecting and promotiong incentives for the development of resistant pathogens including breakpoints
Antibiotic resistance among elderly population
H.R. 3204, The Drug Quality and Security Act and The Compounding Clarity Act of 2013 S. Con. Res. 8 - Concurrent Resolution on the Budget for FY 2014
H. Con. Res. 25 - Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 - Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs; issues related to Medicare reimbursement for new technologies S. Con. Res. 8 - Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 - Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 - Continuing Appropriations Resolution, 2014In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs Implementation of the "GAIN" provision/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) (PL 112-144); antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation; pharmaceutical track and trace legislation or as packaged with/tied to pharmaceutical compounding legislation: H. R. 1919 - Safeguarding America's Pharmaceutical Act of 2013,HR 3204 - Drug Quality and Security Act, HR 2186 VALID Compounding Act, and S. 959 Pharmaceutical Compounding Quality and Accountability Act
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CUBIST PHARMACEUTICALS, INC.
65 Hayden Avenue, Lexington, MA, 02421, US
MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES